Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Access type: UnknownSubject: search.filters.subject.intravaginal brachytherapy

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Brachytherapy alone in the postoperative treatment of stage I endometrial carcinoma
    (Institut za onkologiju Vojvodine, 2018-11-17)
    ;
    ;
    Stojmenovska V
    ;
    ;
    Dimoski I
    Introduction: This study evaluate the local control efficacy and toxicity of postoperative intravaginal brachytherapy (IVBT) alone among patients with endometrial cancer stage I. Material and methods: Between January-2004 and December-2011, 60 stage I endometrial adenocarcinoma patients were treated with IVBT alone, 47 in stage IA, 13 patients in stage IB. The surgical approaches were total abdominal hysterectomy (HTA) and bilateral salpingoopforectomy (BSO) in 45 patients, plus bilateral pelvic, paraaortic lymph node dissection in 15 patients. The mean interval between the surgery and the brachytherapy was 30-37 days. <½ miometrial invasion was found in 48 patients, and >½ in 12 patients. The brachytherapy was applied in 3 weekly fractions of 7Gy per fraction, prescribed at depth of 0,5cm from the applicator surface with HDR, Iridium-192. The mean diameter of the vaginal applicator was 3 (2-3,5) cm. Results: With a mean follow up time of 38 months (12-84), all 60 patients are alive. Reccurence was observed in 5 patients (8,3%): 3 patients experienced local recidiv and 2 patients developed a pelvic mass. The mean rectal dose was estimated 14,1Gy and the mean bladder dose was 13Gy. Acute genitourinary toxicity was observed in 31 patients during the therapy. Vaginal stenosis as late complication occurred in 3 patients. Conclusion: Intravaginal brachytherapy alone in the postoperative treatment of stage I endometrial carcinoma achieves local control associated with acceptable toxicity and minimal morbidity.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    INTRAVAGINAL BRACHYTHERAPY SUPPORTED BY LOCAL ANAESTHESIA IN THE TREATMENT OF ENDOMETRIAL CANCER – SINGLE INSTITUTIONAL EXPERIENCE
    (Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia, 2020-10)
    ;
    ;
    ;
    ;
    Bojoski P
    Intravaginal brachytherapy in endometrial cancer is an inevitable part of the treatment. In the early stages of the disease, it signifcantly reduces the risk of local recurrence in the vaginal cuff with low rates of late toxicity. In the advanced stages, it provides palliative control usually with a hemostyptic effect. Brachytherapy may be the only postoperative treatment – monotherapy, or as a boost following the external beam radiotherapy, depending on many prognostic factors. Placing the vaginal applicator deep into the vagina is certainly an uncomfortable feeling, combined with pain, anxiety and discomfort. Local anaesthesia helps in reducing the painful sensations, gives adequate relaxation, but more importantly provides a quality insight into the condition of the vagina, and thus a successful application. Through our experience with the local vaginal anaesthesia with lidocaine 2% gel, we want to emphasize that intravaginal brachytherapy, supported by local anaesthesia, regardless of the degree of pain relief is directly related to successful treatment.